Accès ouvert

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages in South Africa

Article scientifique 2022 Anglais

Résumé

Abstract Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. We assessed the severity of BA.4/BA.5 infections using the presence/absence of the S-gene target for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We linked national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assessed severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR1.24, 95% CI 0.98–1.55) and severe outcome (aOR 0.71, 95%CI 0.41–1.25) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 continue to show reduced clinical severity compared to previous variants, as observed for Omicron BA.1.

Citer ce document

Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D., Everatt, J., Bhiman, J., Scheepers, C., Tebeila, N., Chiwandire, N., Plessis, M., Govender, N., Ismail, A., Glass, A., Mlisana, K., Stevens, W., Treurnicht, F., Subramoney, K., Makatini, Z., Hsiao, M., Parboosing, R., Wadula, J., Hussey, H., Davies, M., Boulle, A., Gottberg, A., Cohen, C. (2022). Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages in South Africa. https://doi.org/10.21203/rs.3.rs-1792132/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Statistiques

Consultations : 1

Téléchargements : 0